Cargando…

P1126: PHASE 1B/2A STUDY OF AZD4573 (CDK9I) AND ACALABRUTINIB IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL)

Detalles Bibliográficos
Autores principales:	Strati, Paolo, Morschhauser, Franck, Danilov, Alexey, Cheah, Chan, Shah, Harsh, Jurczak, Wojciech, Olabode, Damilola, Meyer, Stefanie, Lim Yoon, Jeong, Arduini, Serena, Saeh, Jamal, Olsson, Richardp, Gregory, Gareth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430950/ http://dx.doi.org/10.1097/01.HS9.0000971400.47925.e9

Ejemplares similares

P1141: ENCOURAGING COMPLETE RESPONSES (CRS) OBSERVED WITH CDK9 INHIBITOR AZD4573 IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) PERIPHERAL T-CELL LYMPHOMA (PTCL): EARLY TRIAL ANALYSIS
por: Shortt, Jake, et al.
Publicado: (2023)

PB1890: ZANUBRUTINIB IN ACALABRUTINIB-INTOLERANT PATIENTS (PTS) WITH B-CELL MALIGNANCIES
por: Shadman, M., et al.
Publicado: (2022)

4573 Characterization of vascular disease in an Acta2 mutant mouse model
por: Kaw, Anita, et al.
Publicado: (2020)

P1129: ACALABRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) MARGINAL ZONE LYMPHOMA (MZL): RESULTS OF A PHASE 2, MULTICENTER, OPEN-LABEL TRIAL
por: Strati, P., et al.
Publicado: (2022)

ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial
por: Davies, Andrew, et al.
Publicado: (2020)

Acalabrutinib for treatment of diffuse large B-cell lymphoma: results from a phase Ib study
por: Strati, Paolo, et al.
Publicado: (2021)

P1210: IMMUNE CORRELATES OF RESPONSE TO GLOFITAMAB: BIOMARKER FINDINGS FROM A PIVOTAL PHASE II EXPANSION STUDY IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
por: Piccione, E. C., et al.
Publicado: (2022)

1126. Three Cases of Neutropenic Enterocolitis Following Midostaurin Administration
por: Carroll, Ryan, et al.
Publicado: (2018)

1126. Variability in Antibiotic Use in Children’s Hospitals in the United States
por: Griffith, Hannah, et al.
Publicado: (2019)

Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r/r DLBCL: phase 1b PORTIA study results
por: Jaeger, Ulrich, et al.
Publicado: (2022)

Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment
por: Roschewski, Mark, et al.
Publicado: (2023)

4th Symposium on Temperature, pts.A - B
por: Brickwedde, Ferdinand Graft, et al.
Publicado: (1962)

DLBCL 1L—What to Expect beyond R-CHOP?
por: Stegemann, Maike, et al.
Publicado: (2022)

1126. Learner Driven Call Center to increase Convalescent Plasma Donation in COVID-19
por: Joyner, Nancy M, et al.
Publicado: (2020)

Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies
por: Abbas, Hussein A., et al.
Publicado: (2021)

P579: SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF AZD5991 IN RELAPSED/ REFRACTORY HEMATOLOGIC MALIGNANCIES: A PHASE 1 FIRST-IN-HUMAN STUDY
por: Desai, Pinkal, et al.
Publicado: (2023)

Acalabrutinib: Disseminated aspergillosis: case report
Publicado: (2022)

Serpentine Supravenous Hyperpigmentation in an HIV Patient Receiving R-CHOP for DLBCL
por: Lancman, Guido, et al.
Publicado: (2018)

Targeting of Inflammatory Pathways with R2CHOP in High-Risk DLBCL
por: Hartert, Keenan T., et al.
Publicado: (2020)

PB2119: LONG-TERM SURVIVAL PROJECTIONS OF LONCASTUXIMAB TESIRINE-TREATED PATIENTS IN RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
por: Hamadani, M., et al.
Publicado: (2022)

Clinical Trials of the BTK Inhibitors Ibrutinib and Acalabrutinib in Human Diseases Beyond B Cell Malignancies
por: Zhu, Sining, et al.
Publicado: (2021)

Outcomes of patients with double/triple expressor diffuse large B-cell lymphoma (DLBCL) treated with R-DA-EPOCH/R-CHOP: A single-center experience.
por: Devi, Kanta, et al.
Publicado: (2021)

P1144: PHASE 2 WAVELINE-004 STUDY: ZILOVERTAMAB VEDOTIN (MK-2140) IN RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
por: Ozcan, Muhit, et al.
Publicado: (2023)

P618: LONG-TERM SAFETY WITH ≥12 MONTHS OF PIRTOBRUTINIB IN RELAPSED/REFRACTORY (R/R) B-CELL MALIGNANCIES
por: Jurczak, Wojciech, et al.
Publicado: (2023)

Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study
por: Belada, David, et al.
Publicado: (2023)

The role of acalabrutinib in adults with chronic lymphocytic leukemia
por: Fakhri, Bita, et al.
Publicado: (2021)

NICE recommends acalabrutinib for chronic lymphocytic leukaemia
Publicado: (2021)

PB1861: ACALABRUTINIB IN THE TREATMENT OF RICHTER SYNDROME
por: Byalik, T., et al.
Publicado: (2022)

PB1948: ACALABRUTINIB IN THE TREATMENT OF RICHTER SYNDROME
por: Byalik, Tatyana, et al.
Publicado: (2023)

Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma
por: Harrington, Bonnie K., et al.
Publicado: (2016)

Exposure–response analysis of acalabrutinib and its active metabolite, ACP‐5862, in patients with B‐cell malignancies
por: Edlund, Helena, et al.
Publicado: (2021)

P625: A PHASE 1B/2 STUDY OF NAVTEMADLIN COMBINED WITH ACALABRUTINIB IN BTK INHIBITOR NAÏVE PATIENTS WITH RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
por: Byrd, John C., et al.
Publicado: (2023)

Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R/R DLBCL
por: Blumenberg, Viktoria, et al.
Publicado: (2023)

Permanent Draft Genome Sequence of Rhizobium sp. Strain LCM 4573, a Salt-Tolerant, Nitrogen-Fixing Bacterium Isolated from Senegalese Soils
por: Diagne, Nathalie, et al.
Publicado: (2017)

CircPCBP2 promotes the stemness and chemoresistance of DLBCL via targeting miR‐33a/b to disinhibit PD‐L1
por: Dong, Lihua, et al.
Publicado: (2022)

Predictive Value of Interim PET/CT in DLBCL Treated with R-CHOP: Meta-Analysis
por: Sun, Na, et al.
Publicado: (2015)

CD24 Contributes to Treatment Effect in ABC-DLBCL Patients with R-CHOP Resistance
por: Qiao, Li-Yan, et al.
Publicado: (2021)

Multifaceted Immunomodulatory Effects of the BTK Inhibitors Ibrutinib and Acalabrutinib on Different Immune Cell Subsets – Beyond B Lymphocytes
por: Zhu, Sining, et al.
Publicado: (2021)

Safety and antitumor activity of acalabrutinib for relapsed/refractory B‐cell malignancies: A Japanese phase I study
por: Izutsu, Koji, et al.
Publicado: (2021)

COVID-19 Infection in Patients With Chronic Lymphocytic Leukemia Receiving Acalabrutinib in the Phase 3B ASSURE Study
por: Niemann, Carsten U., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bflcqa4qcmroqc9u352f252716